These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18563832)

  • 41. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
    Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors.
    Liederer BM; Liu X; Berezhkovskiy LM; Cain G; Ding X; Gaudino J; Kaus R; Plise EG; Sutherlin DP; Harstad EB
    Xenobiotica; 2012 May; 42(5):456-65. PubMed ID: 22122353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin.
    Eberhart DC; Gemzik B; Halvorson MR; Parkinson A
    Mol Pharmacol; 1991 Nov; 40(5):859-67. PubMed ID: 1944247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences.
    Mehrotra N; Lal J; Puri SK; Madhusudanan KP; Gupta RC
    Biopharm Drug Dispos; 2007 Jul; 28(5):209-27. PubMed ID: 17410524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
    Liu L; Halladay JS; Shin Y; Wong S; Coraggio M; La H; Baumgardner M; Le H; Gopaul S; Boggs J; Kuebler P; Davis JC; Liao XC; Lubach JW; Deese A; Sowell CG; Currie KS; Young WB; Khojasteh SC; Hop CE; Wong H
    Drug Metab Dispos; 2011 Oct; 39(10):1840-9. PubMed ID: 21742900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.
    Gemma S; Camodeca C; Sanna Coccone S; Joshi BP; Bernetti M; Moretti V; Brogi S; Bonache de Marcos MC; Savini L; Taramelli D; Basilico N; Parapini S; Rottmann M; Brun R; Lamponi S; Caccia S; Guiso G; Summers RL; Martin RE; Saponara S; Gorelli B; Novellino E; Campiani G; Butini S
    J Med Chem; 2012 Aug; 55(15):6948-67. PubMed ID: 22783984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor.
    Liederer BM; Berezhkovskiy LM; Dean BJ; Dinkel V; Peng J; Merchant M; Plise EG; Wong H; Liu X
    Xenobiotica; 2011 Apr; 41(4):327-39. PubMed ID: 21182395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
    Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
    Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
    Ward KW; Azzarano LM; Bondinell WE; Cousins RD; Huffman WF; Jakas DR; Keenan RM; Ku TW; Lundberg D; Miller WH; Mumaw JA; Newlander KA; Pirhalla JL; Roethke TJ; Salyers KL; Souder PR; Stelman GJ; Smith BR
    Drug Metab Dispos; 1999 Nov; 27(11):1232-41. PubMed ID: 10534306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disposition of remoxipride in different species. Species differences in metabolism.
    Widman M; Nilsson LB; Bryske B; Lundström J
    Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters.
    Hayakawa H; Fukushima Y; Kato H; Fukumoto H; Kadota T; Yamamoto H; Kuroiwa H; Nishigaki J; Tsuji A
    Drug Metab Dispos; 2003 Nov; 31(11):1409-18. PubMed ID: 14570774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Considerations about the structure-activity relationships of 8-aminoquinoline antimalarial drugs.
    McChesney JD
    Bull World Health Organ; 1981; 59(3):459-62. PubMed ID: 6976853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382.
    Hutzler JM; Cerny MA; Yang YS; Asher C; Wong D; Frederick K; Gilpin K
    Drug Metab Dispos; 2014 Oct; 42(10):1751-60. PubMed ID: 25035284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
    Påhlman I; Kankaanranta S; Palmér L
    Arzneimittelforschung; 2001 Feb; 51(2):134-44. PubMed ID: 11258043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
    Basavapathruni A; Olhava EJ; Daigle SR; Therkelsen CA; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Dovletoglou A; Richon VM; Pollock RM; Copeland RA; Moyer MP; Chesworth R; Pearson PG; Waters NJ
    Biopharm Drug Dispos; 2014 May; 35(4):237-52. PubMed ID: 24415392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.